Related Experiment Videos
Molecular Events as Targets of Anticancer Drug Therapy
Adorján Aszalós1, Sándor Eckhardt
1Food and Drug Administration, Washington DC, USA.
Abstract:
The aim of this review is to introduce some molecular targets for cancer chemotherapy, with comments on their mode of action, preclinical and clinical results. The representatives of the following groups are covered: phosphorylation inhibitors, protein kinase modulators, receptor antagonists, immunomodulators, differentiating agents, multidrug resistance modulation, telomerase inhibitors, and bioreductive agents.
Insights
This review explores novel molecular targets for cancer chemotherapy, including their mechanisms, and preclinical and clinical outcomes. It covers key drug classes like kinase inhibitors and immunomodulators for improved cancer treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer chemotherapy faces challenges including drug resistance and targeted efficacy.
- Identifying novel molecular targets is crucial for advancing cancer treatment.
Purpose of the Study:
- To review emerging molecular targets for cancer chemotherapy.
- To discuss the mechanism of action, preclinical, and clinical results of these targets.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of various classes of molecularly targeted agents.
Main Results:
- Covers phosphorylation inhibitors, protein kinase modulators, receptor antagonists, immunomodulators, differentiating agents, multidrug resistance modulators, telomerase inhibitors, and bioreductive agents.
- Summarizes their modes of action and therapeutic outcomes.
Conclusions:
- Molecularly targeted therapies offer promising avenues for cancer treatment.
- Further research into these targets can lead to more effective and personalized cancer chemotherapy.